Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00480025 · ClinicalTrials.gov registry record · Phase 3
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
A Phase 3 study, sponsored by GlaxoSmithKline.
- Terminated
- Registry status
- Phase 3
- Development phase
- 2,278
- Enrollment target
NCT00480025 is a Phase 3 study that was terminated before completion, run by GlaxoSmithKline. The registered enrollment target is 2,278 participants.
The verdict
NCT00480025, a Phase 3 study, was terminated before completion, sponsored by GlaxoSmithKline.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 2,278 participants
- Enrollment target
Study Summary
The purpose of this clinical trial is to demonstrate the benefit of the immunotherapeutic product GSK1572932A when given to patients with Non-Small Cell Lung Cancer, after removal of their tumor. A course of 13 injections will be administered over 27 months. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.
Interventions
- BIOLOGICAL Placebo Control
- BIOLOGICAL GSK1572932A Antigen-Specific Cancer Immunotherapeutic
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,278 participants |
| Start Date | 2007-10-04 |
| Est. Completion | 2014-09-23 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00480025
The ClinicalTrials.gov registry entry for NCT00480025 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 2,278 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Control is the first listed.
NCT00480025 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00480025 about?
NCT00480025 is a clinical study titled "GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer". The purpose of this clinical trial is to demonstrate the benefit of the immunotherapeutic product GSK1572932A when given to patients with Non-Small Cell Lung Cancer, after removal of their tumor. A course of 13 injections will be administered over 27 months. The Protocol Posting has been updated in ...
What is the current status of trial NCT00480025?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 2,278 participants. The study started on 2007-10-04. Estimated completion is 2014-09-23.
What interventions are being tested in trial NCT00480025?
The interventions under investigation include: Placebo Control (BIOLOGICAL), GSK1572932A Antigen-Specific Cancer Immunotherapeutic (BIOLOGICAL).
Who is sponsoring clinical trial NCT00480025?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.